State-Level Impacts of Medicare Part D

Supplements and Featured PublicationsState-Level Impacts of Medicare Part D

In recent research, we explored the impact of the Medicare Part D program on hospitalization rates for ambulatory care—sensitive conditions (ACSCs) among elderly Americans.1 Our results indicate that Part D reduced a summary measure of ACSC hospitalization by 20.5 per 10,000, a percentage change of 4.1 percent. This change represents approximately 42,000 admissions, roughly half of the overall reduction in admissions in our 23-state sample during our study period (2005-2007).

In this brief, we explore the state-level implications of the findings from our paper, by estimating the number of avoided hospitalizations in each state.

A Review of the National Estimates

Before we present our state-level estimates, we first review the regression-based estimates from our paper and describe how those estimates can be used to generate a prediction of the number of avoided ACSC hospitalizations due to Part D. (Please note that for the purposes of the current discussion, we restrict attention to our results on the overall rate of ACSC hospitalization. One could generate a similar set of results for each of the condition-specific hospitalization models in our paper, but we do not do that here.) Our regression model estimates the probability of ACSC hospitalization for both individuals 65 years or older and those aged 60 to 64 years, in the years 2005 through 2007, in 23 states. (The states we analyzed were Arizona, Arkansas, California, Colorado, Florida, Hawaii, Iowa, Kentucky, Maryland, Michigan, Nebraska, Nevada, New Jersey, New York, North Carolina, Oregon, Rhode Island, South Carolina, Utah, Vermont, Washington, West Virginia, and Wisconsin.)

A critical component of our analytic strategy was to measure the percentage of the elderly population in each state and year with comprehensive prescription drug coverage. The magnitude of the change in coverage due to Part D varied significantly across states. For example, the coverage rate in Iowa changed from 45 percent to 88 percent in 2005 and 2006, respectively, while the coverage rate in South Carolina changed from 68 percent to 87 percent. Because states experienced differential changes in coverage rates, our analysis explored whether individuals 65 years or older in states with relatively larger increases in drug coverage rates enjoyed more significant reductions in ACSC hospitalization rates than did states with relatively smaller drug coverage increases, relative to individuals 60 to 64 years of age.

The results from our model indicate that absent the improvement in drug coverage rates brought about by Part D, the overall ACSC hospitalization rate in the post—Part D period would have been 20.5 per 10,000 higher than the observed level. Using the 2006 population of those 65 years and older from our sample, 20.3M, this implies that Part D reduced the number of ACSC hospitalizations by approximately 42,000. If one makes the assumption that the same relationship between drug coverage rate changes and the trend in the ACSC hospitalization rate that existed in our 23-state sample also prevailed in the 50 states and the District of Columbia, then our estimate of avoided hospitalizations increases to approximately 76,000 per year. (The number of elderly Medicare beneficiaries nationwide in 2006 was 37.2M.)

Calculating State-Level Estimates

We allocate avoided hospitalizations across states on the basis of both population size and the change in drug coverage rates. Some states (eg, Iowa) experienced a large increase in the drug coverage rates, while others (eg, South Carolina) experienced a relatively smaller increase. Holding population size constant, it makes sense to allocate a relatively larger percentage of the avoided hospitalizations to states with larger coverage increases, and a relatively smaller percentage to states with smaller coverage increases.

First, we estimate the number of newly covered individuals in each state by multiplying the 65-year-and-older population in 2006 by the change in the drug coverage rate. Second, we calculate the impact of drug coverage on the probability of ACSC hospitalization. This is done by dividing the figure from above, 20.5 per 10,000, by the national change in the drug coverage rate (29.4 percent); the calculated value is 69.8 per 10,000. Third, we multiply the number of newly covered individuals in each state by this rate. We also illustrate the differences across states by calculating each state’s share of avoided ACSC hospitalizations, which is equivalent to each state’s share of newly covered individuals.

The results are presented in the Figure and Table. The results indicate that one-third of all newly covered individuals reside in Florida, California, Texas, Pennsylvania, or Ohio. This can be explained in part by the relatively large populations in these states. But some states account for a relatively large share of the avoided hospitalizations. For example, Florida’s share of the Medicare population was 8.1% in 2006, but its share of newly covered individuals was 10.0%. Conversely, California’s Medicare population share was 10.5%, but its share of newly covered individuals was 7.9%.

Implications for Medicare Spending

Recent work by McWilliams and colleagues has estimated the impact of Medicare Part D on nondrug spending.2 Using individual level data on prescription drug insurance coverage from the Health and Retirement Study linked together with Medicare enrollment and insurance claims information, the authors find that among individuals moving from limited or no drug coverage before Part D to drug coverage under the new program, non-prescription drug spending declined by $1224 per year. Together with our estimates of the increase in drug coverage due to Part D, these results imply an overall savings of approximately $13.4B in the first year of the program’s operation (10,940,181 newly covered beneficiaries times $1224 in annual savings from nondrug offsets per beneficiary). This represents more than one-fourth of the program’s total cost in 2007 ($49.5B), its first full calendar year of existence after the transition year of 2006.3

This study was supported by the Pharmaceutical Research and Manufacturers of America.

Christopher C. Afendulis, PhD

Lecturer in Health Care Policy

Department of Health Care Policy

Harvard Medical School

Boston, Massachusetts

Michael E. Chernew, PhD

Professor of Health Care Policy

Department of Health Care Policy

Harvard Medical School

Boston, Massachusetts

  1. Afendulis CC, He Y, Zaslavsky AM, Chernew ME. The impact of Medicare Part D on hospitalization rates. Health Serv Res. 2011:46(4):1022-1038.
  2. McWilliams JM, Zaslavsky AM, Huskamp HA. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA. 2011;306(4):402-409.
  3. 2008 Annual Report of the Board of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, page 112, Table III.C17.
© 2023 MJH Life Sciences
All rights reserved.